Advice

following a resubmission assessed under the orphan process:

mexiletine (Namuscla®) is accepted for use within NHSScotland.

Indication under review: for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.

In a short-term, phase III, crossover study, mexiletine significantly improved muscle stiffness compared with placebo when measured on a visual analogue scale.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
mexiletine (Namuscla)
SMC ID:
SMC2307
Indication:

Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.

Pharmaceutical company
Lupin Healthcare
BNF chapter
Central nervous system
Submission type
Resubmission
Status
Accepted
Date advice published
07 December 2020